Skip to content
  • Follow Us
CarboHyde
  • Home
  • Cyclodextrin Masterclass XIV
  • Nutraceutical Complexes
  • About Us
  • Pipeline
  • CarboHyde’s Blog
  • News
  • Home
  • Cyclodextrin Masterclass XIV
  • Nutraceutical Complexes
  • About Us
  • Pipeline
  • CarboHyde’s Blog
  • News
CarboHyde
  • Home
  • Cyclodextrin Masterclass XIV
  • Nutraceutical Complexes
  • About Us
  • Pipeline
  • CarboHyde’s Blog
  • News

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Nov 7, 2022Tamas Sohajdadrug developmentcholesterol, clinical trial, cyclodextrin, rare disease

Cyclo Therapeutics, Inc. (Caroline Hastings, Benny Liu, Bryan Hurst, Gerald Cox and Sharon Hrynkow) Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Artikle: https://www.sciencedirect.com/science/article/pii/S109671922200419X

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Prev
Next
Developed by Shuttle Themes. Powered by WordPress.
  • Contact Us
  • LinkedIn
  • Twitter
  • Privacy Policy